Monochinqué retard, 50 mg capsules 30 pcs

Pharmacodynamics

Peripheral vasodilator with predominant effect on the venous vessels. Antianginal drug.

Limits preload (by enlarging the peripheral veins) and postload (by reducing PPS), reduces myocardial oxygen demand. Dilates coronary arteries and improves coronary blood flow, promotes its redistribution to ischemic areas, reduces left ventricular end-diastolic volume and reduces systolic stress on its walls. Increases exercise tolerance in patients with coronary artery disease, reduces the pressure in the small circle of the circulation.

At the molecular level it acts through the formation of nitric oxide (NO) and cyclic guanosine monophosphate (cGMP), reducing the concentration of calcium in smooth muscle cells.

The special dosage form of Monocinqué® retarded release of the active ingredient provides therapeutic concentrations of the drug in the blood within 24 hours after taking a single daily dose.

The drug is recommended for long-term therapy.

Pharmacokinetics

Isosorbide-5-monononitrate is quickly and completely absorbed from the GI tract after oral administration. Bioavailability of the drug when administered orally is from 90 to 100%. Cmax in blood plasma is reached 1-1.5 hours after intake.

It is not subjected to the effect of “first passage” through the liver.

Elimation

Isosorbide-5-monononitrate is excreted by the kidneys exclusively as metabolites. Approximately 2% is excreted unchanged.

The T1/2 is approximately 5 h, which is approximately 8 times higher than that of isosorbide dinitrate.

Indications

Active ingredient

Composition

Active ingredients:

Isosorbide-5-monononitrate 50 mg.

Auxiliary substances:

sucrose,

corn starch,

How to take, the dosage

Monocinqué® Retard is indicated at 50 mg (1 capsule) once daily in the morning after a meal, without chewing and with a small amount of fluid.

The dose should be adjusted according to the patient’s condition.

Interaction

In concomitant administration of Monochinqué® retard with other vasodilators, antihypertensive drugs, beta-adrenoblockers, calcium channel blockers, antipsychotic drugs, tricyclic antidepressants, sildenafil, ethanol may potentiate the hypotensive effect of Monochinqué® retard.

Special Instructions

The drug is not used to stop attacks of angina pectoris.

In arterial hypertension the drug is used only under medical supervision.

The drug is indicated both as monotherapy and in combination with beta-adrenoblockers, calcium channel blockers, ACE inhibitors, cardiac glycosides or diuretics.

Impact on ability to drive vehicles and other mechanisms requiring high concentration

The drug may decrease the ability to concentrate and the speed of psychomotor reactions when taking it; therefore, driving vehicles and engaging in other potentially dangerous activities are not recommended.

Contraindications

Side effects

No side effects have been described when taking Monocinqué® Retard at the recommended dose.

However, as with the use of other nitrates, it is possible:

Cardiovascular system: at the beginning of treatment – “nitrate” headache, which usually decreases after a few days with continuation of therapy; after the first dose or after increasing the dose – arterial (including orthostatic) hypotension, accompanied by tachycardia, dizziness, weakness.

Digestive system disorders: very rarely – nausea, vomiting.

Dermatological reactions: very rare – redness of the face and skin allergic reactions.

Overdose

No cases of overdose have been reported.

Similarities